Preferred Label : Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002;
NCIt synonyms : iADC NBE-002; ADC NBE-002; Anthracycline-based Immune-stimulatory ADC NBE-002; Anti-ROR1/PNU-159682 Derivative ADC NBE-002;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against
the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1
(ROR1) site-specifically conjugated to a derivative of the highly potent anthracycline
PNU-159682, with potential antineoplastic activity. Upon intravenous administration,
the monoclonal antibody moiety of NBE-002 targets and binds to ROR1 expressed on tumor
cells. Upon binding and internalization, the anthracycline-based toxin intercalates
into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication
and repair, and prevents RNA and protein synthesis. This kills the ROR1-expressing
cancer cells. In addition, the PNU-159682 derivate may promote immunogenic cell death
(ICD) and activate a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response,
thereby further killing the ROR1-expressing tumor cells. ROR1, also known as neurotrophic
tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and
by certain leukemias. It plays key roles in tumor cell proliferation and survival.;
Molecule name : NBE-002; NBE 002;
NCI Metathesaurus CUI : CL1407925;
Origin ID : C174012;
UMLS CUI : C5418052;
Semantic type(s)
- concept_is_in_subset
- has_target
